Blood-derived anti-inflammatory protein solution blocks the effect of IL-1# on human macrophages in vitro

February 26, 2020


Objective: The purpose of this research  was to determine if an autologous protein solution (APS), prepared from platelet-rich plasma (PRP), could reduce the deleterious effects of inflammatory cytokines in vitro.

Methods: APS was prepared by processing human blood in a tuned density buoy separation device (Platelet Separation System, Biomet Biologics, LLC) to produce platelet-rich plasma (PRP) and processing the PRP in a concentration device containing polyacrylimide beads to produce a highly concentrated anti-inflammatory solution. A functional assay was designed using recombinant interleukin (IL)-1b to upregulate IL-8 production by human mono-cytes. Either recombinant human interleukin-1 receptor antagonist (rhIL-1ra) or APS was added to some samples to determine if a reduced inflammatory response could be identified in vitro. The enzyme-linked immuno-sorbent assay (ELISA) method was employed to perform cytokine analyses, and Student’s t test (a = 0.05) was used for all statistical analyses.

Results: Both the rhIL-1ra and the APS reduced the effect of IL-1b on human macrophages in vitro. This was mea- sured by the reduced production of IL-8 and tumor necrosis